Lung Neoplasm Malignant
1 competing product in clinical development for Lung Neoplasm Malignant.
Pipeline by Phase
Phase 1/21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue Medications | Daiichi Sankyo | Phase 1/2 | Recruiting | 39 |